Oncology & Cancer

Single-dose PCV13 immunogenic, safe in pediatric oncology

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in Cancer.

Diseases, Conditions, Syndromes

Team publishes longitudinal work on pneumonia

A Marshall University Joan C. Edwards School of Medicine research team has published findings that show patients who recover from invasive pneumococcal pneumonia, on average, live 10 years less when measured against life ...

Medical research

Team uses Google analytical tool to gauge vaccine effectiveness

Using a statistical method initially developed by Google, a Yale School of Public Health-led research team has devised a novel way to better analyze the impact of vaccines. The research was published in the Proceedings of ...

Medications

Seniors need two pneumonia vaccines, CDC advisory panel says

(HealthDay)—Adults 65 and older need two vaccines to better protect them from bacterial infection in the blood (called sepsis), meningitis and pneumonia, according to a revised vaccination schedule from the 2015 Advisory ...

Pediatrics

PCV13 recommended for 6- to 18-year-olds at high risk

(HealthDay)—Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according to a policy statement published ...

page 1 from 3